The US biotech says it will establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.
Having built up its mRNA expertise with its COVID-19 vaccine, Pfizer now sets out its strategy for the future. “Going forward, we plan to continue to capitalize on the leadership we have built in both mRNA R&D and manufacturing."